aclidinium vs fluticasone/umeclidinium/vilanterol
Side-by-side comparison of aclidinium and fluticasone/umeclidinium/vilanterol. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Trelegy Ellipta
No summary available.
Trelegy Ellipta is a medicine that contains three drugs in one inhaler. It helps people with COPD and asthma breathe easier.
Information not available.
Trelegy Ellipta is used to help people with chronic obstructive pulmonary disease (COPD) breathe better. It is also used to treat asthma in adults aged 18 and older. This medicine is not for sudden breathing problems.
Information not available.
Trelegy Ellipta contains three medicines that work in different ways. Fluticasone reduces swelling in the lungs. Umeclidinium and vilanterol relax the muscles around your airways, making it easier to breathe.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Upper respiratory infection
- • Pneumonia
- • Bronchitis
- • Oral thrush (Candida)
- • Headache
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
No adverse event reports.
No specific warnings noted.
LABA medicines like vilanterol can raise the risk of asthma-related problems. Do not use Trelegy Ellipta for sudden, severe COPD or asthma symptoms. Rinse your mouth after use to prevent thrush. Trelegy Ellipta may increase your risk of pneumonia. It can also weaken your immune system and raise your risk of infections. It may cause problems with your heart, blood pressure, blood sugar, or bones. Long-term use may lead to glaucoma or cataracts. Tell your doctor if your glaucoma or urinary retention gets worse.
No pregnancy information available.
Not enough information exists to determine if Trelegy Ellipta is safe during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if this medicine passes into breast milk.
Also Compare, Nearby Drugs
Compare aclidinium with
How to Read This aclidinium vs fluticasone/umeclidinium/vilanterol Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while fluticasone/umeclidinium/vilanterol sits within the Triple Therapy (ICS/LAMA/LABA) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while fluticasone/umeclidinium/vilanterol has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between aclidinium and fluticasone/umeclidinium/vilanterol - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.